01
Selecting immune checkpoint blockade
dMMR or MSI-H can inform checkpoint-inhibitor selection according to tumor type, stage, and drug indication. For colorectal cancer, CAP/ASCO favor MMR IHC and/or MSI-PCR, with appropriately validated MSI-NGS considered an alternative.
Assay and specimen: In CRC, IHC for all four MMR proteins and/or MSI-PCR; validation of NGS against reference methods is important.
Clinical interpretation: Interpret and report MSI/dMMR in the context of tumor type, specimen quality, and internal controls.
02
Endometrial cancer and Lynch syndrome assessment
For endometrial carcinoma, CAP/ASCO favor MMR IHC for mismatch-repair-related treatment decisions. Protein loss patterns can guide referral for hereditary assessment.
Assay and specimen: IHC for MLH1, PMS2, MSH2 and MSH6; when MLH1/PMS2 are lost, consider MLH1 promoter methylation assessment in the appropriate context.
Clinical interpretation: Tumor dMMR alone does not diagnose Lynch syndrome. Somatic causes and MLH1 methylation also need consideration.
03
Discordant MMR and MSI results
Discordance, such as proficient MMR by IHC with MSI-H by a molecular test, calls for review of pathology, block quality, and, where appropriate, repeat or orthogonal testing.
Assay and specimen: Review IHC internal positive controls, tumor fraction, loci or MSI-NGS algorithm, and panel coverage.
Clinical interpretation: High TMB is not a surrogate for dMMR under CAP/ASCO guidance.